BR0215081A - Purified Hepatitis C Virus Wrap Proteins for Diagnostic and Therapeutic Use - Google Patents

Purified Hepatitis C Virus Wrap Proteins for Diagnostic and Therapeutic Use

Info

Publication number
BR0215081A
BR0215081A BR0215081-6A BR0215081A BR0215081A BR 0215081 A BR0215081 A BR 0215081A BR 0215081 A BR0215081 A BR 0215081A BR 0215081 A BR0215081 A BR 0215081A
Authority
BR
Brazil
Prior art keywords
relates
proteins
wrap
diagnostic
present
Prior art date
Application number
BR0215081-6A
Other languages
Portuguese (pt)
Inventor
Geert Maertens
Erik Depla
Fons Bosman
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of BR0215081A publication Critical patent/BR0215081A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

"PROTEìNAS PURIFICADAS DO ENVOLTóRIO DO VìRUS DE HEPATITE C PARA USO DIAGNóSTICO E TERAPêUTICO". A presente invenção se refere a um processo para a purificação de proteínas do envoltório de HCV simples ou oligoméricas específicas recombinantes selecionadas do grupo que consistem em E1 e/ou E2 e/ou E1/E2, caracterizado pelo fato de que, depois de se submeter a lise as células hospedeiras transformadas para se isolar a proteína expressa de modo recombinante, é conduzida uma etapa de redução ou clivagem de ligação dissulfeto com um agente de clivagem de ligação dissulfeto. A presente invenção também se refere a uma composição isolada por tal processo. A presente invenção também se refere à aplicação diagnóstica e terapêutica destas composições. Além disso, a invenção se, refere ao emprego da proteína E1 de HCV e de seus peptídeos para o prognóstico e a monitoração da eficácia clínica e/ou do resultado clínico de tratamento contra HCV."HEPATITE C VIRUS PURIFIED PROTEINS FOR DIAGNOSIS AND THERAPEUTIC USE". The present invention relates to a process for the purification of recombinant single HCV-wrap proteins or specific recombinant oligomeric selected from the group consisting of E1 and / or E2 and / or E1 / E2, characterized in that, after undergoing lysis of the transformed host cells to isolate the recombinantly expressed protein, a disulfide binding reduction or cleavage step is conducted with a disulfide binding cleavage agent. The present invention also relates to a composition isolated by such process. The present invention also relates to the diagnostic and therapeutic application of these compositions. Furthermore, the invention relates to the use of HCV E1 protein and its peptides for prognosis and monitoring of clinical efficacy and / or clinical outcome of HCV treatment.

BR0215081-6A 2001-12-18 2002-12-18 Purified Hepatitis C Virus Wrap Proteins for Diagnostic and Therapeutic Use BR0215081A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2051001A 2001-12-18 2001-12-18
US41835802P 2002-10-16 2002-10-16
PCT/EP2002/014480 WO2003051912A2 (en) 2001-12-18 2002-12-18 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use

Publications (1)

Publication Number Publication Date
BR0215081A true BR0215081A (en) 2004-10-19

Family

ID=26693530

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0215081-6A BR0215081A (en) 2001-12-18 2002-12-18 Purified Hepatitis C Virus Wrap Proteins for Diagnostic and Therapeutic Use

Country Status (12)

Country Link
EP (1) EP1461080A2 (en)
JP (1) JP2005516939A (en)
KR (1) KR20040076869A (en)
CN (1) CN1622828A (en)
AU (1) AU2002361160B2 (en)
BR (1) BR0215081A (en)
CA (1) CA2468690A1 (en)
IL (1) IL162236A0 (en)
MX (1) MXPA04005891A (en)
NZ (1) NZ533396A (en)
RU (1) RU2319505C2 (en)
WO (1) WO2003051912A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7108855B2 (en) 1998-06-24 2006-09-19 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
US7101561B2 (en) 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
OA13092A (en) 2001-04-24 2006-11-10 Innogenetics Nv Constructs and methods for expression of recombinant HCV envelope proteins.
FR2859221B1 (en) * 2003-08-28 2005-10-14 Centre Nat Rech Scient VECTOR FOR CO-EXPRESSING MEMBRANE DOMAINS OF ENVELOPE PROTEINS OF A VIRUS AND USES THEREOF
EP1574517A1 (en) 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
CN101437964B (en) * 2004-10-18 2012-06-13 全球免疫股份有限公司 Yeast-based therapy for chronic hepatitis c infection
CN100365124C (en) * 2005-10-27 2008-01-30 云南大学 Determination and application of hepatitis C virus specific cDNA sequence
WO2009030872A1 (en) * 2007-09-07 2009-03-12 Mats Axel Atterdag Persson Materials and methods for the treatment of hepatitis c
DK2285408T3 (en) 2008-06-05 2019-02-04 Ablynx Nv AMINO ACID SEQUENCES AGAINST COATING PROTEINS IN A VIRUS AND POLYPEPTIDES INCLUDING THESE FOR TREATMENT OF VIRUSAL DISEASES
EP2438087B1 (en) 2009-06-05 2017-05-10 Ablynx N.V. Trivalent anti human respiratory syncytial virus (hrsv) nanobody constructs for the prevention and/or treatment of respiratory tract infections
EP2507262A1 (en) 2009-11-30 2012-10-10 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
BR112013032381B1 (en) 2011-06-14 2021-01-12 Globeimmune, Inc. yeast-based compositions and methods for treating or preventing infection by the hepatitis delta virus
RU2570553C2 (en) * 2013-11-20 2015-12-10 Федеральное бюджетное учреждение "Всероссийский научно-исследовательский институт лесоводства и механизации лесного хозяйства (ФБУ ВНИИЛМ) Method for viral polyhedron decontamination
CN104327170A (en) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 Sequence of hepatitis c virus (HCV) cell-entrance-inhibiting peptide ZTE1 and application
EP3194595A4 (en) 2014-09-17 2018-06-20 University of Iowa Research Foundation Viral rna segments as immunomodulatory agents and vaccine components
AU2017334263A1 (en) * 2016-09-29 2019-04-04 Macfarlane Burnet Institute For Medical Research And Public Health Limited Assembled glycoproteins
US20220041650A1 (en) * 2018-12-03 2022-02-10 Duke University Purification method for recombinant proteins and nanoparticles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0992580B1 (en) * 1993-11-04 2005-03-09 Innogenetics N.V. Immunodominant human T-cell epitopes of Hepatitis C virus
NZ508797A (en) * 1998-06-24 2004-02-27 Innogenetics N Particles of HCV envelope proteins: use for vaccination

Also Published As

Publication number Publication date
JP2005516939A (en) 2005-06-09
CN1622828A (en) 2005-06-01
WO2003051912A9 (en) 2004-07-15
IL162236A0 (en) 2005-11-20
AU2002361160B2 (en) 2008-07-03
MXPA04005891A (en) 2004-09-13
RU2004116914A (en) 2005-04-20
KR20040076869A (en) 2004-09-03
AU2002361160A1 (en) 2003-06-30
WO2003051912A3 (en) 2004-03-04
NZ533396A (en) 2005-04-29
EP1461080A2 (en) 2004-09-29
CA2468690A1 (en) 2003-06-26
RU2319505C2 (en) 2008-03-20
WO2003051912A2 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
BR0215081A (en) Purified Hepatitis C Virus Wrap Proteins for Diagnostic and Therapeutic Use
WO1996004385A3 (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
Starcher et al. Purification and comparison of elastins from different animal species
AU744184B2 (en) Peptide with radio protective effect
BR0109494A (en) Production of recombinant blood clotting factors in human cell lines
EP1484339A3 (en) Kallikrein-inhibiting "Kunitz Domain" proteins and nucleic acids encoding the same
BR9712518A (en) Polypeptide, DNA molecule, expression vector, host cell, pharmaceutical composition, vaccine, fusion protein, process for detecting tuberculosis in a patient, and diagnostic kit
BR0116370A (en) Compound, pharmaceutical composition, use of a compound, and method of treating an hppar-mediated disease or condition in a patient.
DE69637914D1 (en) VEGETABLE AGAINST VIRUS RESPONSIBLE FOR RESPIRATORY AND REPRODUCTIVE DISEASES IN PIGS
DE69940439D1 (en) STREPTOCOCCUS PNEUMONIAE PROTEINS AND IMMUNOGENIC FRAGMENTS FOR IMPORTS
DE69922958D1 (en) HCV HULL PROTEINS PARTICLES: USE FOR THERAPEUTIC VACCINATION
BRPI0409624A (en) Benzamide 2-hydroxy-3-diaminoalkanes
WO2000077216A3 (en) Porcine circovirus vaccine in recombinant poxvirus
BR9809445A (en) Polypeptide comprising an immunogenic portion of a m antigen. tubercolosis, dna molecule, expression vector, host cell, pharmaceutical composition, vaccine, fusion protein, processes for inducing protective immunity in a patient, tuberculosis detection process in a patient, and, diagnostic kit.
MX9703643A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein.
ATE371373T1 (en) PROTEINS ENCODED BY POLYNUCLIC ACIDS BY THE PORGINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
BR0214188A (en) Monoclonal antibodies to hepatitis viruses and / or fragments thereof with binding activity and use thereof
Rose et al. Proteolytic fragmentation and peptide mapping of human carboxyamidomethylated tracheobronchial mucin
BR0309570A (en) Chimeric Camp Factors for Streptococcus Infection Vaccination
BR9607628A (en) Biologically isolated proteinaceous molecule, recombinant molecule, peptide fragment, nucleic acid molecule, pharmaceutical composition, and processes for preparing a recombinant molecule and for inducing astroglial proliferation in a mammal
Wu et al. Conformation of naturally-occurring peptides in surfactant solution: its relation to the structure-forming potential of amino acid sequence
BR0203518A (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use
BR0206995A (en) Hepatitis B virus treatment
BRPI0211635B8 (en) cyclohexyl sulfone compound, its use, and pharmaceutical composition

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.